Staff Scientist II
Labcorp Drug Development
Dr. Bingbing Wang is a Method Development Lead in the Bioanalytical Services of Labcorp Drug Development, developing and validating ligand binding and cell-based assays for evaluation of the pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of different biotherapeutic modalities. Bingbing received her B.S. in Chemistry from Shandong University, China in 2001, then earned her Ph.D. in Polymer Science & Engineering from Peking University in 2006. After that, Bingbing accepted a position as a postdoctoral researcher at Drexel University in Philadelphia, PA, studying polymer-modified nanoparticle from 2006 to 2009. From 2011 to 2012, Bingbing continued her postdoctoral research at Northeastern University in Boston, MA, developing chemical sensors with nanoparticles and carbon-nanotube. In 2012, Bingbing joined the Institute of Drug Discovery at Purdue University with Professor Philip Low working for 6 years in the field of immunotherapy by targeting activated macrophages in cancer and inflammatory diseases of rheumatoid arthritis and idiopathic pulmonary fibrosis. In 2018, Bingbing joined the Bioanalytical Services team of Covance (becoming Labcorp Drug Development in 2021) as a Staff Scientist in the Method Development team at the Indianapolis, IN site, where she has a passion for evaluating new techniques and technologies to bring advanced capabilities into the regulated bioanalysis space.
Disclosure information not submitted.
Monday, October 17, 2022
10:30 AM – 11:00 AM ET